T. Rowe Price Associates
BEAM icon

T. Rowe Price Associates’s Beam Therapeutics BEAM Stock Holding History

T. Rowe Price Associates’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Buy
3,415,239
+702,009
+26% +$21.2M 0.01% 654
2026
Q1 		$64.7M Sell
2,713,230
-17,052
-0.6% -$473K 0.01% 710
2025
Q4 		$75.7M Buy
2,730,282
+467,133
+21% +$11.9M 0.01% 691
2025
Q3 		$54.9M Sell
2,263,149
-179,727
-7% -$3.58M 0.01% 779
2025
Q2 		$41.6M Sell
2,442,876
-583,825
-19% -$10.2M ﹤0.01% 773
2025
Q1 		$59.1M Buy
3,026,701
+1,273,559
+73% +$33.4M 0.01% 673
2024
Q4 		$43.5M Buy
1,753,142
+266,834
+18% +$6.81M 0.01% 798
2024
Q3 		$36.4M Buy
1,486,308
+92,635
+7% +$2.39M ﹤0.01% 841
2024
Q2 		$32.7M Buy
1,393,673
+147,484
+12% +$3.62M ﹤0.01% 838
2024
Q1 		$41.2M Buy
1,246,189
+1,207,699
+3,138% +$37.6M 0.01% 775
2023
Q4 		$1.05M Buy
38,490
+2,165
+6% +$53.8K ﹤0.01% 1852
2023
Q3 		$874K Buy
36,325
+2,100
+6% +$56.3K ﹤0.01% 1858
2023
Q2 		$1.09M Buy
34,225
+3,656
+12% +$119K ﹤0.01% 1759
2023
Q1 		$937K Buy
30,569
+971
+3% +$38.3K ﹤0.01% 1822
2022
Q4 		$1.16M Buy
29,598
+2,553
+9% +$114K ﹤0.01% 1694
2022
Q3 		$1.29M Buy
27,045
+3,560
+15% +$203K ﹤0.01% 1630
2022
Q2 		$909K Buy
23,485
+1,549
+7% +$61.6K ﹤0.01% 1945
2022
Q1 		$1.26M Buy
21,936
+3,136
+17% +$206K ﹤0.01% 1890
2021
Q4 		$1.5M Sell
18,800
-4,393
-19% -$376K ﹤0.01% 1824
2021
Q3 		$2.02M Sell
23,193
-2,691
-10% -$270K ﹤0.01% 1722
2021
Q2 		$3.33M Sell
25,884
-25,939
-50% -$2.07M ﹤0.01% 1591
2021
Q1 		$4.15M Buy
51,823
+41,630
+408% +$3.96M ﹤0.01% 1508
2020
Q4 		$832K Buy
+10,193
New +$501K ﹤0.01% 2015
2020
Q3 		– Sell
-444,449
Closed -$12.4M – 2593
2020
Q2 		$12.4M Sell
444,449
-11,998
-3% -$259K ﹤0.01% 1252
2020
Q1 		$8.22M Buy
+456,447
New +$9.92M ﹤0.01% 1263

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

T. Rowe Price Associates's BEAM Position: Q2 2026 in Review

T. Rowe Price Associates increased its Beam Therapeutics (BEAM) stake by 26% in Q2 2026, buying an estimated $21.2M and bringing the position to 3,415,239 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #654.

T. Rowe Price Associates first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • T. Rowe Price Associates held 3,415,239 shares of Beam Therapeutics worth $117M as of Q2 2026.
  • T. Rowe Price Associates bought 702,009 Beam Therapeutics shares in Q2 2026, an estimated $21.2M.
  • Beam Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #654 holding.
  • T. Rowe Price Associates first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.